Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial.

IF 2.3 Q3 CLINICAL NEUROLOGY

Neurodegenerative disease management Pub Date : 2021-08-01 Epub Date: 2021-07-09 DOI:10.2217/nmt-2020-0061

Emma Gulley, Joe Verghese, Helena M Blumen, Emmeline Ayers, Cuiling Wang, Russell K Portenoy, Jessica L Zwerling, Erica Weiss, Helena Knotkova

{"title":"Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial.","authors":"Emma Gulley, Joe Verghese, Helena M Blumen, Emmeline Ayers, Cuiling Wang, Russell K Portenoy, Jessica L Zwerling, Erica Weiss, Helena Knotkova","doi":"10.2217/nmt-2020-0061","DOIUrl":null,"url":null,"abstract":"New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT04404153 (Clinicaltrials.gov).","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"11 4","pages":"277-288"},"PeriodicalIF":2.3000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438943/pdf/nmt-11-277.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2020-0061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT04404153 (Clinicaltrials.gov).

查看原文本刊更多论文

阿尔茨海默病认知增强的神经刺激(NICE-AD研究):一项随机临床试验

迫切需要新的治疗阿尔茨海默病(AD)症状的方法。先前的研究表明，经颅直流电刺激(tDCS)是一种无创的神经调节方法，可能是一种安全且潜在有效的治疗方法，但结论受到小样本量和短暂刺激方案的限制。这项双盲随机试验涉及100名患有轻度至中度AD的老年人，研究了6个月的在家活动tDCS或在背外侧前额叶皮质上进行假手术的效果。主要结果是整体认知表现。次要结果包括执行控制/空间选择性注意、功能性神经可塑性、抑郁症状、生活质量和刺激期后3个月效果的持久性。该结果将为数月在家tDCS治疗AD的有效性提供证据。=临床试验标识符NCT04404153 (Clinicaltrials.gov)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurodegenerative disease management CLINICAL NEUROLOGY-

CiteScore

4.30

自引率

0.00%

发文量